|OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial …|
C Aghajanian, SV Blank, BA Goff, PL Judson, MG Teneriello, A Husain, ...
Journal of clinical oncology 30 (17), 2039, 2012
|Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer|
K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ...
New England Journal of Medicine 379 (26), 2495-2505, 2018
|Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial|
ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ...
Journal of Clinical Oncology 20 (12), 2824-2831, 2002
|Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial|
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
|A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies|
C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ...
Clinical cancer research 8 (8), 2505-2511, 2002
|Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm|
DS Chi, EL Eisenhauer, O Zivanovic, Y Sonoda, NR Abu-Rustum, ...
Gynecologic oncology 114 (1), 26-31, 2009
|The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center|
NR Abu-Rustum, K Alektiar, A Iasonos, G Lev, Y Sonoda, C Aghajanian, ...
Gynecologic oncology 103 (2), 714-718, 2006
|Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma|
DS Chi, K McCaughty, JP Diaz, J Huh, S Schwabenbauer, AJ Hummer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2006
|The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer|
EL Eisenhauer, NR Abu-Rustum, Y Sonoda, DA Levine, EA Poynor, ...
Gynecologic oncology 103 (3), 1083-1090, 2006
|Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.|
D Fennelly, C Aghajanian, F Shapiro, C O'flaherty, M McKenzie, ...
Journal of Clinical Oncology 15 (1), 187-192, 1997
|Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status|
MS Gordon, D Matei, C Aghajanian, UA Matulonis, M Brewer, GF Fleming, ...
Journal of Clinical Oncology 24 (26), 4324-4332, 2006
|Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study|
C Aghajanian, MW Sill, KM Darcy, B Greer, DS McMeekin, PG Rose, ...
Journal of clinical oncology 29 (16), 2259, 2011
|Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient|
A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ...
Cell 170 (5), 927-938. e20, 2017
|Identification of six new susceptibility loci for invasive epithelial ovarian cancer|
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
|Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients|
P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ...
Clinical cancer research 18 (23), 6497-6508, 2012
|Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer|
RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ...
New England Journal of Medicine 381 (25), 2403-2415, 2019
|A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary …|
RL Coleman, MW Sill, K Bell-McGuinn, C Aghajanian, HJ Gray, KS Tewari, ...
Gynecologic oncology 137 (3), 386-391, 2015
|Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer|
C Aghajanian, B Goff, LR Nycum, YV Wang, A Husain, SV Blank
Gynecologic oncology 139 (1), 10-16, 2015
|Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature|
L Dos Santos, E Mok, A Iasonos, K Park, RA Soslow, C Aghajanian, ...
Gynecologic oncology 105 (2), 321-324, 2007
|Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study|
ML Hensley, N Ishill, R Soslow, J Larkin, N Abu-Rustum, P Sabbatini, ...
Gynecologic oncology 112 (3), 563-567, 2009